Thrivent Financial for Lutherans
NVAX icon

Thrivent Financial for Lutherans’s Novavax NVAX Stock Holding History

Thrivent Financial for Lutherans’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$542K Sell
57,554
-5,088
-8% -$45.6K ﹤0.01% 2282
2026
Q1 		$510K Sell
62,642
-13,945
-18% -$126K ﹤0.01% 2212
2025
Q4 		$515K Buy
+76,587
New +$577K ﹤0.01% 2247
2025
Q3 		– Sell
-209,641
Closed -$1.32M – 2539
2025
Q2 		$1.32M Buy
+209,641
New +$1.39M ﹤0.01% 1613
2021
Q2 		– Sell
-37,494
Closed -$6.8M – 2504
2021
Q1 		$6.8M Buy
+37,494
New +$7.47M 0.02% 793
2015
Q1 		– Sell
-13,218
Closed -$1.57M – 1842
2014
Q4 		$1.57M Sell
13,218
-905
-6% -$94.6K 0.01% 744
2014
Q3 		$1.18M Buy
+14,123
New +$1.28M 0.01% 824

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $605M AUM 43.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Thrivent Financial for Lutherans's NVAX Position: Q2 2026 in Review

Thrivent Financial for Lutherans reduced its Novavax (NVAX) stake by 8.1% in Q2 2026, selling an estimated $45.6K and leaving 57,554 shares worth $542K. The position accounts for ﹤0.01% of the portfolio, ranked #2282.

Thrivent Financial for Lutherans first reported a position in NVAX in Q3 2014 and has held it in 7 quarters since. The position peaked at $6.8M in Q1 2021. 268 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

  • Thrivent Financial for Lutherans held 57,554 shares of Novavax worth $542K as of Q2 2026.
  • Thrivent Financial for Lutherans sold 5,088 Novavax shares in Q2 2026, an estimated $45.6K.
  • Novavax made up ﹤0.01% of Thrivent Financial for Lutherans's portfolio in Q2 2026, its #2282 holding.
  • Thrivent Financial for Lutherans first reported a position in Novavax in Q3 2014 and has held it in 7 quarters since.
  • Thrivent Financial for Lutherans's Novavax position peaked at $6.8M in Q1 2021.
  • 268 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2026, filed 14 Aug 2026.